John Aballi's most recent trade in Exagen Inc was a trade of 150,000 Common Stock done . Disclosure was reported to the exchange on March 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 150,000 | 839,834 (6%) | 1% | 0 | Common Stock | |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 100,000 | 175,000 | - | - | Stock Option(right to buy) | |
| Exagen Inc | John Aballi | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.62 per share. | 03 Mar 2026 | 15,698 | 687,299 (5%) | 0% | 3.6 | 56,827 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.08 per share. | 03 Mar 2026 | 2,535 | 689,834 (5%) | 0% | 3.1 | 7,800 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 24 Feb 2026 | 11,430 | 702,997 (5%) | 0% | 3.6 | 41,262 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.82 per share. | 16 Oct 2025 | 31,787 | 714,427 (5%) | 0% | 11.8 | 375,598 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.47 per share. | 28 Feb 2025 | 8,621 | 746,214 (5%) | 0% | 2.5 | 21,251 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 112,500 | 737,593 (5%) | 0% | 0 | Common Stock | |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 75,000 | 75,000 | - | - | Stock Option(right to buy) | |
| Exagen Inc | John Aballi | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.81 per share. | 14 Nov 2024 | 24,305 | 689,799 (5%) | 0% | 2.8 | 68,297 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 16 May 2024 | 40,401 | 40,401 (0%) | 0% | 1.9 | 77,570 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.91 per share. | 29 Feb 2024 | 9,804 | 600,788 (4%) | 0% | 1.9 | 18,726 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 175,000 | 590,984 (4%) | 1% | 0 | Common Stock | |
| Exagen Inc | John Aballi | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.68 per share. | 08 Dec 2022 | 90,000 | 440,000 (3%) | 0% | 2.7 | 241,200 | Common Stock |
| Exagen Inc | John Aballi | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2022 | 350,000 | 350,000 | - | 0 | Restricted Stock Units |